Acarbose Improves Hypoglycaemia Following Gastric Bypass Surgery Without Increasing Glucagon-Like Peptide 1 Levels

Simple item page
dc.contributor.authorPatricio Valderas, Juan
dc.contributor.authorAhuad, Jessica
dc.contributor.authorRubio, Lorena
dc.contributor.authorEscalona, Manuel
dc.contributor.authorPollak, Felipe
dc.contributor.authorMaiz, Alberto
dc.date.accessioned2025-01-20T23:58:55Z
dc.date.available2025-01-20T23:58:55Z
dc.date.issued2012
dc.description.abstractPostprandial hypoglycaemia is a severe complication of Roux-en-Y gastric bypass (RYGBP). Acarbose, an alpha-glucosidase inhibitor (AGI), is employed in its treatment. Several studies have shown that AGIs increase the postprandial levels of glucagon-like peptide 1 (GLP-1). However, an excessive level of GLP-1 is one of the factors involved in the physiopathology of this condition. We analysed the effect of acarbose oral administration in eight RYBGP patients with clinically significant hypoglycaemia or dumping syndrome.
dc.description.abstractGlucose, insulin and GLP-1 plasma levels in fasting and after ingestion of a standard meal (Ensure PlusA (R); 13 g protein, 50 g carbohydrate, 11 g fat) were measured. The test was repeated the following week with the oral administration of 100 mg of acarbose 15 min prior to the meal.
dc.description.abstractFive patients developed asymptomatic hypoglycaemia during the test (glucose level < 50 mg/dl) with inappropriately high insulin levels and exaggerated GLP-1 response. Acarbose ingestion avoided hypoglycaemia in all of the patients and increased the lowest plasma glucose level (46.4 +/- 4.8 vs. 59.0 +/- 2.6 mg/dl, p < 0.01). Acarbose ingestion decreased the area under the curve for serum insulin and GLP-1 levels at 15 min after the meal.
dc.description.abstractAcarbose avoided postprandial hypoglycaemia following RYGBP by decreasing the hyperinsulinemic response. This was associated with a decrease in early GLP-1 secretion, in contrast to that observed in non-surgical subjects. This finding could be explained by the reduction of glucose load in the jejunum produced by the alpha-glucosidase inhibition, which is the main stimulus for GLP-1 secretion.
dc.description.funderDepartment of Nutrition, Diabetes, and Metabolism, School of Medicine, Pontificia Universidad Catolica de Chile
dc.fuente.origenWOS
dc.identifier.doi10.1007/s11695-011-0581-0
dc.identifier.issn0960-8923
dc.identifier.urihttps://doi.org/10.1007/s11695-011-0581-0
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/95270
dc.identifier.wosidWOS:000301481200011
dc.issue.numero4
dc.language.isoen
dc.pagina.final586
dc.pagina.inicio582
dc.revistaObesity surgery
dc.rightsacceso restringido
dc.subjectGlucagon-like peptide 1
dc.subjectAcarbose
dc.subjectHypoglycaemia
dc.subjectGastric bypass
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAcarbose Improves Hypoglycaemia Following Gastric Bypass Surgery Without Increasing Glucagon-Like Peptide 1 Levels
dc.typeartículo
dc.volumen22
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas